

LIS008039627B2

(12) United States Patent

Gano

(54) SUBSTITUTED
3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO

(75) Inventor: **Kyle W. Gano**, San Diego, CA (US)

(73) Assignee: Neurocrine Biosciences, Inc., San

Diego, CA (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 698 days.

(21) Appl. No.: 11/937,445

(22) Filed: Nov. 8, 2007

(65) Prior Publication Data

US 2008/0167337 A1 Jul. 10, 2008

Related U.S. Application Data

(60) Provisional application No. 60/864,944, filed on Nov. 8, 2006.

(51) **Int. Cl. C07D 455/06** (2006.01) **A01N 43/42** (2006.01)

(52) **U.S. Cl.** **546/95**; 514/294

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

2,843,591 A 7/1958 Brossi et al. 2,852,518 A 9/1958 Morgan 3,209,005 A 9/1965 Brossi et al. 2003/0087803 A1 5/2003 Latvin et al.

FOREIGN PATENT DOCUMENTS

WO	W091/16920 A1	11/1991
WO	WO99/30561 A1	6/1999
WO	WO2005/077946 A1	8/2005
WO	WO2006/053067 A2	5/2006
WO	WO2007/005283 A2	1/2007
WO	WO2007/007105 A1	1/2007
WO	W02007/017643 A1	2/2007
WO	WO2007/017654 A1	2/2007

OTHER PUBLICATIONS

Aranda et al. European Journal of Medicinal Chemistry, 25, 369-374, 1990 *

Kilbourn et al. Chirality, 9, 59062, 1997.*

Vig et al. Pharmaceutical Research, 20 (9), 1381-1388, 2003.* Cho et al., Annual Reports in Medicinal chemistry, 41, 395-407, 2006.*

Communication pursuant to Article 94(3) (Form 2906) in EP App. No. 07864160.2 mailed Aug. 13, 2009.

Stock, A. M. et al, Structure and Tautomerism of the Esters of Several beta-Substituted Pyruvic Acids, Journal of Organic Chemistry, 1958, 1840-1848, 23

(10) **Patent No.:**

US 8,039,627 B2

(45) Date of Patent:

Oct. 18, 2011

Pletscher, A. et al, Benzoquinolizine Derivatives: A New Class of Monoamine Decreasing Drugs with Psychotropic Action, International Review of Neurobiology, 1962, 275-306.

Schwarz, D. E. et al, Metabolice Studies of Tetrabenazine, A Psychotropic Drug in Animals and Man, Biochemical Pharmacology, 1966, 645-655, 15.

Pritsch, L. E. et al, On the Pharmacology of a Benzoquinolizine Derivative: Ro-1284, Prarmacology 1969, 113-123, 2.

Mehvar, R. et al, Direct Injection High-Performance Liquid Chromatography of Tetrabenazine and Its Metabolite in Plasma of Humans and Rats, Journal of Pharmaceutical Sciences, 1986, 1006-1009, 75(10).

Mehvar, R. et al, Pharmacokinetics of Tetrabenazine and Is Major Metabolite in Man and Rat, Drug Metabolism and Disposition, 1987, 250-255, 15(2).

Aranda, G. et al, Synthesis and biological activity of iodinated and photosensitive derivatives of tetrabenazine, European Journal of Medicinal Chemistry, 1990, 369-374, 25.

Kilborn, M. et al, Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific, European Journal of Pharmacology, 1995, 249-252, 278.

Lee, L. C., In Vitro and In Vivo Studies of Benzisoquinoline Ligands for the Brain Synaptic Vesicle Monoamine Transporter, Journal of Medicinal Chemistry, 1996, 191-196, 39.

Kilborn, M.R. et al, Absolute Configuration of (+)-alpha-Dihyrdotertabenazine, an Active Metabolite of Tetrabenazine. Chirality, 1997, 59-62, 9.

Vig, B. S. et al, Amino Acid Ester Prodrugs of Floxuridine: Synthesis and Effects of Structure, Stereochemistry, and Site of Esterification on the Rate of Hydrolysis, 2003, 1381-1388, 20(9). Kim, I. et al, A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein, Molecular Pharmaceutics, 2004, 117-127, 1(2).

Song, X., et al, Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Mediated Transport, Molecular Pharmaceutics, 2005, 157-167, 2(2).

(Continued)

Primary Examiner — Nizal Chandrakumar (74) Attorney, Agent, or Firm — Seed IP Law Group PLLC

(57) ABSTRACT

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds are disclosed that are inhibitors of the vesicular monoamine transporter 2 (VMAT2). The compounds of this invention have the structure:

wherein R_1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.



US 8,039,627 B2

Page 2

OTHER PUBLICATIONS

Lorenz!, P. L. et al, Amino Acid Ester Prodrugs of 2-Bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole Enhance Metabolic Stability in Vitro and in Vivo, The Journal of Pharmacology and Experimental Therapeutics, 2005, 883-890, 314(2).

Zheng, G. et al, Vesicular Monoamine Transporter 2: Role as a Novel Target for Drug Development, The AAPS Journal, 2006, 682-692, 8(4).

Cho, A., Recent Advances in Oral Prodrug Discovery, Annual Reports in Medicinal Chemistry, 2006, 395-407, 41.

Zheng, F. et al, Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2, Bioorganic and Medicinal Chemistry, 2007, 2975-2992, 15.

* cited by examiner






Figure 1b








Figure 1c

















Figure 3a Plasma Concentration-Time Profile of 10 mg/kg PO of 3-1 and 10 mg/kg PO of 1d.1 to male rats (N=3)

10000 - 1d.1 @ 10mg/kg 3-1 PO - 1d.1 @ 10mg/kg 1d.1 PO - 1d.1 @ 10mg/kg 1d.1 PO - 1d.1 @ 10mg/kg 3-1 PO - 1d.1 @ 10mg/kg 3-1 PO - 1d.1 @ 10mg/kg 1d.1 PO - 1d.1 @ 10mg/kg 1d.1 PO - 1d.1 @ 10mg/kg 1d.1 PO

Figure 3b
Plasma Concentration-Time Profile
of 10 mg/kg PO of 2-1 to Male Rats
(N=3)




Figure 3c
Plasma Concentration-Time Profile
of 6.1 mg/kg PO of 3-1 to Male
Dogs (N=3)





Figure 3d
Plasma Concentration-Time Profile
of 10 mg/kg PO of 2-1 to Male Dogs
(N=3)



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

